Mimi Wan

Mimi Wan

Auto-generated profile, based on publicly available information

Mimi Wan

National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing, 210023, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MWMimi Wan
Mimi Wan
QWQi Wang
Qi Wang
RWRongliang Wang
Rongliang Wang
WRWu Rui
Wu Rui
TLTing Li
Ting Li
DSDongquan Shi
Dongquan Shi
The treatment difficulties of venous thrombosis include short half-life, low utilization, and poor penetration of drugs at thrombus site. Here, we develop one kind of mesoporous/macroporous silica/platinum nanomotors with platelet membrane (PM) modification (MMNM/PM) for sequentially targeting delivery of thrombolytic and anticoagulant drugs for thrombus treatment. Regulated by the special proteins on PM, the nanomotors target the thrombus site and then PM can be ruptured under near-infrared (NIR) irradiation to achieve desirable sequential drug release, including rapid release of thrombolytic urokinase (3 hours) and slow release of anticoagulant heparin (>20 days). Meantime, the motion ability of nanomotors under NIR irradiation can effectively promote them to penetrate deeply in thrombus site to enhance retention ratio. The in vitro and in vivo evaluation results confirm that the synergistic effect of targeting ability from PM and motion ability from nanomotors can notably enhance the thrombolysis effect in both static/dynamic thrombus and rat model.

4 January 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
CYChunhao Yang
Chunhao Yang
YXYunxin Xue
Yunxin Xue
YDYu Duan
Yu Duan
CMChun Mao
Chun Mao
MWMimi Wan
Mimi Wan

13 October 2022 in ACS Nano
Verified
Journal Article
Closed access
WJWentao Jiang
Wentao Jiang
ZWZiyu Wu
Ziyu Wu
ZGZheng Gao
Zheng Gao
MWMimi Wan
Mimi Wan
MZMin Zhou
Min Zhou
Jian ShenJian Shen
Jian Shen

20 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHuan Chen
Huan Chen
TLTing Li
Ting Li
ZLZhiyong Liu
Zhiyong Liu
STShuwan Tang
Shuwan Tang
JTJintao Tong
Jintao Tong
MWMimi Wan
Mimi Wan
The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor sites accurately and properly activate complex immune responses. Herein, we design and prepare a kind of chemotactic nanomotor loaded with brain endothelial cell targeting agent angiopep-2 and anti-tumor drug (Lonidamine modified with mitochondrial targeting agent triphenylphosphine, TLND). Reactive oxygen species and inducible nitric oxide synthase (ROS/iNOS), which are specifically highly expressed in glioblastoma microenvironment, are used as chemoattractants to induce the chemotactic behavior of the nanomotors. We propose a precise targeting strategy of brain endothelial cells-tumor cells-mitochondria. Results verified that the released NO and TLND can regulate the immune circulation through multiple steps to enhance the effect of immunotherapy, including triggering the immunogenic cell death of tumor, inducing dendritic cells to mature, promoting cytotoxic T cells infiltration, and regulating tumor microenvironment. Moreover, this treatment strategy can form an effective immune memory effect to prevent tumor metastasis and recurrence.

29 July 2021 in ACS Nano
Verified
Journal Article
Closed access
ALAnlong Liu
Anlong Liu
QWQi Wang
Qi Wang
ZZZinan Zhao
Zinan Zhao
WRWu Rui
Wu Rui
MWMaochun Wang
Maochun Wang
CMChun Mao
Chun Mao

27 May 2024 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
ZWZiyu Wu
Ziyu Wu
LCLin Chen
Lin Chen
WGWenyan Guo
Wenyan Guo
JWJun Wang
Jun Wang
HNHaiya Ni
Haiya Ni
MWMimi Wan
Mimi Wan